


From Early Detection to Tumor “Education”: Syantra’s Bold Bet on cfRNA in Cancer Tech
A New Direction in Liquid Biopsy When Syantra Inc. announced

Merck KGaA in Talks to Acquire U.S. Biotech Firm SpringWorks, Valued at $4 Billion
Merck KGaA, Darmstadt, Germany, is reportedly in advanced negotiations to

German Biotech CatalYm Raises $150 Million for Phase 2b Cancer Studies
CatalYm, a German biotech company specializing in cancer immunotherapy, has

Myricx Bio’s NMTi-ADCs Achieve Tumor Regression in Preclinical Trials
The field of cancer treatment is on the cusp of
